Friday, 13 Jul 2018

You are here

Obesity Surgery Tames Knee OA Pain

Laparoscopic gastric band (LAGB) surgery was associated with significant decreases in knee pain from osteoarthritis (OA), with the greatest improvements seen among those whose body mass index (BMI) had the greatest decreases and among younger patients, researchers reported.

Among patients whose BMI decreases following bariatric surgery exceeded 13 kg/m2, pain reduction from baseline was 4.23 points on a 0-10 scale, whereas the decrease was only 2.59 points for those whose BMI decline was less than 8 kg/m2, according to Jonathan Samuels, MD, and colleagues from NYU Langone Medical Center in New York City.

And for patients age 40 and under, the pain improvements were 4.41 points compared with 4.11 for those 41 to 50, 3.25 for those 51 to 60, and only 2.11 among those older than 60, the researchers reported in Seminars in Arthritis & Rheumatism.

Osteoarthritis is now the leading cause of musculoskeletal disability in the U.S., and available treatments are insufficiently effective and can be associated with major toxicities.

Obesity is arguably the most modifiable risk factor for knee OA, doubling the lifetime risk for the progressively painful condition. Many organizations, including the American College of Rheumatology and the Osteoarthritis Research Society International, advocate weight loss as a therapeutic strategy for decreasing knee pain.

The National Institutes of Health guidelines on bariatric surgery recommend the more aggressive procedures of gastric bypass and sleeve gastrectomy for patients whose BMI is 35 or higher and who have at least one comorbid condition, and also the less invasive LAGB for patients with less severe obesity (BMI of 30 or higher) and one or more comorbidities.

"Yet most insurance companies deny coverage for the LAGB in the 30 to 35 kg/m2 range, despite early evidence that moderately obese patients achieve a significant reduction of knee OA pain following the less aggressive LAGB procedure," Samuels and colleagues wrote.

In order to identify groups of patients who might have the greatest benefits from bariatric surgery and should therefore consider it earlier, before irreparable knee damage occurs, the researchers reviewed the Weight Management Program Research Registry for patients who had one of the bariatric procedures from 2002 to 2015. Eligible patients completed a telephone survey on pain 1 year after the surgery and in the subsequent years.

Of the 120 patients who had the LAGB surgery, mean age was 49.7, and more than three-quarters were white women. The mean baseline BMI was 46.3, and mean knee pain score was 6.88.

One-third of the patients had previously had a knee injury, and one in five had prior knee surgery. A total of 47% had OA in sites other than the knee, and 53% had a family history of OA.

A year after surgery, the mean BMI had declined by 11.2 kg/m2 to an average of 35.1 (P<0.00), while knee pain decreased to a mean score of 3.34 (P<0.001). Higher baseline BMI did not predict the degree of knee pain reduction, as might have been expected. "Thus, as suggested by the recent guidelines on comorbidities of obesity, LAGB may be a viable treatment method for those with BMI of 30 kg/m2 or higher, even though insurers generally do not reimburse unless the BMI is at least 35 kg/m2," the researchers wrote.

"We thought it would be helpful to show that people with more modest obesity can do really well with the surgery," Samuels told MedPage Today.

The mean time between the surgery and the survey was 9.14 years. By that point, knee pain scores had declined further, to a mean of 2.84 (P=0.054), and mean BMI was 33.8.

Having had a serious knee injury before the development of OA was associated with less of an improvement in pain, with mean changes in pain scores of 2.87, but a prior history of knee surgery showed no association. There also was no difference for sex or family history, and those with OA at multiple sites had less improvement.

"For obese patients who have persistent and severe knee pain from osteoarthritis, weight loss surgery should be considered a treatment option regardless of age," Samuels said.

"Understandably, as older individuals are more likely to have advanced OA, the greater knee pain reduction among younger individuals may have resulted to some extent because they had less severe OA than their older counterparts," the team concluded. "Still, younger patients who are not originally candidates for LAGB should be reconsidered if they also have debilitating knee OA pain."

Limitations of the study, the researchers said, included its retrospective design and the lack of radiographic evidence of knee OA.

The study received no funding.

One co-author reported consulting for Arrow Inc.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source:

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.